LENOVO
14.6.2022 12:02:08 CEST | Business Wire | Press release
Lenovo (HKSE: 992) (ADR: LNVGY) has today officially opened the doors to its first in-house manufacturing facility in Europe. Based in Ullo, Hungary, the factory focuses primarily on building server infrastructure, storage systems and high-end PC workstations used by customers throughout the Europe, Middle East, and Africa region.
Extending Lenovo’s international manufacturing operations, the investment represents significant economic potential for both the private and public sectors in Hungary, with increased production capacity, greater potential for collaboration with local vendors, and the creation of new job openings. The site already employs over 1,000 full-time staff in a variety of engineering, management & operational roles, with numbers continuing to increase as the facility moves towards full capacity.
Strong infrastructure, skilled labor and a location at the center of Europe made Hungary the natural location for Lenovo’s first European in-house manufacturing facility. In addition, part of Lenovo’s investment has been supported with local government incentives through the Hungarian Investment Promotion Agency (HIPA).
Francois Bornibus, Senior Vice President and EMEA President, at Lenovo, commented: “With our manufacturing facility in Hungary officially open, we’ve reached a profound milestone in our global manufacturing network optimization and evolution. Hungary’s well-connected location puts us much closer to our European customers so that we can fulfil and sustain their needs while remaining at the forefront of innovation. As our business continues to grow around the world, this incredible new facility will play a key role in our plans to ensure future success and bring smarter technology for all to Europe more sustainably, quickly and efficiently.”
Róbert Ésik, CEO of the Hungarian Investment Promotion Agency (HIPA), added: “We are delighted that Lenovo, an industry leader with a long-established history in global manufacturing, has chosen to cooperate with us and locate its new facility in Hungary. With the site now officially open, we expect to see new collaboration opportunities for local suppliers contribute towards Hungary’s prosperous economic environment.”
Covering almost 50,000 square meters across two buildings and three floors, the new site is one of Lenovo’s largest manufacturing facilities. The production line can produce more than 1,000 servers and 4,000 workstations a day – each one built specifically to customer requirements. Innovative automation capabilities are equipped throughout, including a first-class building management system operating on the shop floor and logistics area to monitor temperature, humidity, asset conditions and DIMM robotic labeling. This enables Lenovo to maintain optimal quality control of its products.
The new purpose-built building has been fitted with solar panels with a capacity of 0.5 megawatts – enough energy to power the equivalent of a small village. Building devices locally also dramatically reduces the freight miles these products incur, providing more efficient and sustainable transportation options. This combined with innovative manufacturing processes, such as Lenovo’s patented low-temperature solder process, will help Lenovo achieve its science-based climate goals .
The Hungary facility is part of Lenovo’s global manufacturing and supply chain strategy that serves customers in 180 markets from 35+ manufacturing sites around the world – including Argentina, Brazil, China, Germany, Hungary, India, Japan, Mexico and the USA. Lenovo is widely recognized for its global hybrid manufacturing model that includes a mix of both in-house and contract manufacturing. A key source of competitive advantage for the company, it provides greater efficiency and control over product development and supply chain operations, enabling customer needs to be responded to more effectively.
In May 2022, Lenovo jumped seven places in a year, and is now ranked #9 in the Gartner Global Supply Chain Top 25 for 2022 . The recognition highlights Lenovo’s leadership as a purpose-driven organization and operational center of excellence in the global supply chain community.
In addition to creating new job opportunities in and around Ullo, Lenovo continues its commitment to support the local community through philanthropic activities such as technology donations for local schools and charities.
About Lenovo:
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$70 billion revenue global technology powerhouse, ranked #159 in the Fortune Global 500, employing 75,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s leading PC player by expanding into new growth areas of infrastructure, mobile, solutions and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com , and read about the latest news via our StoryHub .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005180/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
